✦ LIBER ✦

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Scribed by Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Liau, K.; Noe, D.; Healey, D.; Huberman, M.

Book ID: 122922182
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 148 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(04)80145-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation study of epide

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Phase II Study of Cediranib, an Oral Pan

Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

✍ Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Plotkin, S. R.; G 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 107 KB

Clinical phase I study of elpamotide, a

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

✍ Okamoto, Isamu; Arao, Tokuzo; Miyazaki, Masaki; Satoh, Taroh; Okamoto, Kunio; Ts 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

An Evaluation of the Drug Interaction Po

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

✍ Goh, B C; Reddy, N J; Dandamudi, U B; Laubscher, K H; Peckham, T; Hodge, J P; Su 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 291 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Phase I Clinical and Pharmacokinetic Stu

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

✍ Strumberg, D. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB